These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 33150)

  • 21. A derivative of rifamycin SV inhibiting rifampicin-resistant RNA polymerase of Escherichia coli.
    Nikiforov VG; Trapkova AA; Gragerov AI; Maslin DN
    FEBS Lett; 1982 Dec; 150(2):416-8. PubMed ID: 6761147
    [No Abstract]   [Full Text] [Related]  

  • 22. Rifampin: mechanisms of action and resistance.
    Wehrli W
    Rev Infect Dis; 1983; 5 Suppl 3():S407-11. PubMed ID: 6356275
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Relationship between the bacterial resistance induced by rifamdin and the RNA polymerase].
    Zhang X; Jiang T; Li X; Wang Y
    Hua Xi Yi Ke Da Xue Xue Bao; 1991 Mar; 22(1):75-8. PubMed ID: 1774042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rifampin Resistance rpoB Alleles or Multicopy Thioredoxin/Thioredoxin Reductase Suppresses the Lethality of Disruption of the Global Stress Regulator spx in Staphylococcus aureus.
    Villanueva M; Jousselin A; Baek KT; Prados J; Andrey DO; Renzoni A; Ingmer H; Frees D; Kelley WL
    J Bacteriol; 2016 Oct; 198(19):2719-31. PubMed ID: 27432833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. beta' subunit of bacterial RNA polymerase is responsible for streptolydigin resistance in Bacillus subtilis.
    Halling SM; Burtis KC; Doi RH
    Nature; 1978 Apr; 272(5656):837-9. PubMed ID: 417268
    [No Abstract]   [Full Text] [Related]  

  • 26. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis.
    Williams DL; Spring L; Collins L; Miller LP; Heifets LB; Gangadharam PR; Gillis TP
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1853-7. PubMed ID: 9661035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular genetic and structural modeling studies of Staphylococcus aureus RNA polymerase and the fitness of rifampin resistance genotypes in relation to clinical prevalence.
    O'Neill AJ; Huovinen T; Fishwick CW; Chopra I
    Antimicrob Agents Chemother; 2006 Jan; 50(1):298-309. PubMed ID: 16377701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HelR is a helicase-like protein that protects RNA polymerase from rifamycin antibiotics.
    Surette MD; Waglechner N; Koteva K; Wright GD
    Mol Cell; 2022 Sep; 82(17):3151-3165.e9. PubMed ID: 35907401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rifamycin inhibition of WT and Rif-resistant Mycobacterium tuberculosis and Escherichia coli RNA polymerases in vitro.
    Gill SK; Garcia GA
    Tuberculosis (Edinb); 2011 Sep; 91(5):361-9. PubMed ID: 21704562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Streptolydigin resistance can be conferred by alterations to either the beta or beta' subunits of Bacillus subtilis RNA polymerase.
    Yang X; Price CW
    J Biol Chem; 1995 Oct; 270(41):23930-3. PubMed ID: 7592585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of resistance to ciprofloxacin, rifampin, and mupirocin in methicillin-susceptible and -resistant Staphylococcus aureus isolates.
    Schmitz FJ; Fluit AC; Hafner D; Beeck A; Perdikouli M; Boos M; Scheuring S; Verhoef J; Köhrer K; Von Eiff C
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3229-31. PubMed ID: 11036061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus.
    Aubry-Damon H; Soussy CJ; Courvalin P
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2590-4. PubMed ID: 9756760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives.
    Fujii K; Tsuji A; Miyazaki S; Yamaguchi K; Goto S
    Antimicrob Agents Chemother; 1994 May; 38(5):1118-22. PubMed ID: 8067748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new class of small molecule RNA polymerase inhibitors with activity against rifampicin-resistant Staphylococcus aureus.
    Arhin F; Bélanger O; Ciblat S; Dehbi M; Delorme D; Dietrich E; Dixit D; Lafontaine Y; Lehoux D; Liu J; McKay GA; Moeck G; Reddy R; Rose Y; Srikumar R; Tanaka KS; Williams DM; Gros P; Pelletier J; Parr TR; Far AR
    Bioorg Med Chem; 2006 Sep; 14(17):5812-32. PubMed ID: 16759869
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rifampin-resistant mutants of Myxococcus xanthus defective in development.
    Rudd K; Zusman DR
    J Bacteriol; 1979 Jan; 137(1):295-300. PubMed ID: 104962
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biological cost of rifampin resistance from the perspective of Staphylococcus aureus.
    Wichelhaus TA; Böddinghaus B; Besier S; Schäfer V; Brade V; Ludwig A
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3381-5. PubMed ID: 12384339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance of Escherichia coli to rifampicin and sorangicin A--a comparison.
    Römmele G; Wirz G; Solf R; Vosbeck K; Gruner J; Wehrli W
    J Antibiot (Tokyo); 1990 Jan; 43(1):88-91. PubMed ID: 1689709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Enzymes of the Rifamycin Antibiotic Resistome.
    Surette MD; Spanogiannopoulos P; Wright GD
    Acc Chem Res; 2021 May; 54(9):2065-2075. PubMed ID: 33877820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Linking system-wide impacts of RNA polymerase mutations to the fitness cost of rifampin resistance in Pseudomonas aeruginosa.
    Qi Q; Preston GM; MacLean RC
    mBio; 2014 Dec; 5(6):e01562. PubMed ID: 25491352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequency, spectrum, and nonzero fitness costs of resistance to myxopyronin in Staphylococcus aureus.
    Srivastava A; Degen D; Ebright YW; Ebright RH
    Antimicrob Agents Chemother; 2012 Dec; 56(12):6250-5. PubMed ID: 23006749
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.